Input or output interoperability
DICOM is explicitly referenced in the described input, output, or workflow.
exact submission · checked 2026-09-01The model card does not establish every supported DICOM object, transfer method, or local interface.
FDA-cleared profile
ScanMed, LLC
'ProstatID is a radiological computer assisted detection (CADe) and diagnostic (CADx)software device for use in a healthcare facility or hospital to assist trained radiologists in the detection, assessment, and characterization of prostate abnormalities, including cancer lesions using MR image data with the following indications for Use. ProstatID analyzes T2W, DWI and ADC MRI data. ProstatID does not include DCE images inits analysis. ProstatID software is intended for use as a concurrent reading aid for physicians interpreting prostate MRI exams of patients presented for high-risk screening or diagnostic imaging, from compatible MRI systems, to identify regions suspicious for prostate cancer and assess their likelihood of malignancy. Output of the device includes the volume of the prostate and locations, as well as the extent of suspect lesions, with index scores indicating the likelihood that cancer is present, as well as an exam score by way of PI-RADs interpretation suggestion. 'Extent of suspect lesions' refers to both the assessment of the boundary of a particular abnormality, as well as identification of multiple abnormalities. In cases where multiple abnormalities are present, ProstatID can be used to assess each abnormality independently. Outputs of this device should be interpreted with all available MR data consistent with ACRclinical recommendations (e.g., dynamic contract enhanced images if available) in context of PIRADsv2, and in conjunction with bi-parametric MRI acquired with either surface or endorectal MRI accessory coils from compatible MRI systems. Analysis by ProstatID is not intended as a replacement for interpreting prostate abnormalities using MR image data consistent with clinical recommendations (including DCE); nor should patient management decisions be made solely based on ProstatID.'
Clinical fit
Start with the authorized purpose, then verify how it fits your service line and reading workflow.
Exact-submission indication text from the ACR AI Central model card. FDA labeling remains controlling.
Intended-user text reported in the exact-submission ACR model card.
Patient-population text reported in the exact-submission ACR model card; institutional setting may still require vendor confirmation.
Conservative normalization of explicit wording in an exact-submission source.
Conservative normalization of explicit wording in an exact-submission source.
Clinical output reported in the exact-submission ACR model card.
Limitations and supported-acquisition details reported in the exact-submission ACR model card.
Regulatory identity
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
Imaging modality reported in the exact-submission ACR AI Central model card.
Anatomy normalized from explicit exact-submission ACR model-card wording.
Implementation
Use these fields to structure a vendor demo, security review, and implementation estimate.
Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.
Deployment category preserved from the prior exact-submission review; hosting region, data flow, and current commercial configuration still require vendor confirmation.
FDA authorization does not establish the current commercial security posture. Request data-flow diagrams, hosting and retention details, access controls, audit logging, attestations, and incident-response documentation.
Training, onboarding, competency, and support commitments are commercial implementation details that require current vendor documentation.
Local acceptance testing, production monitoring, drift review, update control, and incident escalation require a current vendor and site-specific governance plan.
DICOM is explicitly referenced in the described input, output, or workflow.
exact submission · checked 2026-09-01The model card does not establish every supported DICOM object, transfer method, or local interface.
Scanner manufacturers: GE;Philips;Siemens
exact submission · checked 2026-09-01Confirm currently supported software versions, protocols, and site-specific acquisition configurations.
Evidence
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version.
Structured study metadata from the exact-submission ACR model card; this is not an independent evidence synthesis.
This field has not been curated yet.
This field has not been curated yet.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Stand-alone performance and reader study (ACR AI Central category) · Adult
exact submission · Tested version: Exact product version not reported; regulatory study summarized for FDA submission K212783 · n=150 · Independence not establishedK212783
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Economics and lifecycle
These are common procurement questions; unknown values remain visible until a source supports them.
FDA submission materials do not establish current commercial pricing. Request the pricing unit, term, minimum commitment, implementation fees, and included support from the vendor.
Determine whether any product-specific CPT/HCPCS pathway exists and separate it from billing for the underlying imaging service.
Safety and lifecycle
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.
Buyer worksheet
Research record
This audit distinguishes completed source review from fields that have not yet been researched.
Exact-submission ACR model-card fields were normalized under the current provenance rules; vendor and independent-study confirmation remain distinct. Automated exact-name discovery found 1 PubMed and 0 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads remain unpublished until a human confirms the exact product and tested version.
Source classes: fda ai list, fda decision summary, acr ai central product, pubmed, clinical trials, openfda device recall
Sources
Sources accessed through 2026-09-02.
Alternatives
Quantib B.V.
FDA product code QDQ identifies this device class as Radiological Computer Assisted Detection/Diagnosis Software For Lesions Suspicious For Cancer. A radiological computer...
Quibim S.L.
FDA product code QDQ identifies this device class as Radiological Computer Assisted Detection/Diagnosis Software For Lesions Suspicious For Cancer. A radiological computer...
Siemens Healthcare GmbH
Prostate MR AI (VA10A) is a plug-in CADe/CADx aid for radiologists interpreting prostate MRI in adult men aged 40 years or older with suspected prostate cancer and no prior...
JLK Inc.
FDA product code QIH identifies this device class as Automated Radiological Image Processing Software. To provide automated radiological image processing and analysis tools....